Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975647 · ClinicalTrials.gov registry record · Phase 3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
A Phase 3 study of HER2-positive Breast Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
- 20
- Study locations
NCT03975647: Active Phase 3 study of HER2-positive Breast Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT03975647 is a Phase 3 study of HER2-positive Breast Cancer that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 466 participants, above the 228-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (104% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03975647, a Phase 3 study of HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer. Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills or placebo pills two times every day. Patients will get T-DM1 injections from the study site staff on the first day of every cycle.
Primary Outcome
PFS as per investigator was defined as the time from the date of randomization to the investigator assessment of disease progression (PD) as per RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimiter (mm). Participants without documentation o
Conditions Studied
Interventions
- DRUG placebo
- DRUG T-DM1
- DRUG tucatinib
Study Locations (20)
California
- UCLA Hematology/Oncology - Alhambra - Alhambra
- Kaiser Permanente Medical Center Lab Drawing Station - Antioch
- Kaiser Permanente Medical Center Lab Drawing Station - Antioch
- UCLA Hematology/Oncology- Beverly Hills - Beverly Hills
- UC Irvine Health Cancer Center - Newport - Costa Mesa
- City of Hope Investigational Drug Services (IDS) - Duarte
- City of Hope(City of Hope National Medical Center,City of Hope Medical Center) - Duarte
- Kaiser Permanente Medical Center (Radiology) - Dublin
- UCLA Hematology/Oncology - Encino - Encino
- Kaiser Permanente Medical Center Lab Drawing Station - Fairfield
- Kaiser Permanente Medical Center Lab Drawing Station - Gilroy
Arizona
- Banner Gateway Medical Center - Gilbert
- Banner MD Anderson Cancer Center - Gilbert
- Western Regional Medical Center, LLC - Goodyear
- Arizona Oncology Associates, PC - HOPE. - Tucson
- Arizona Oncology Associates, PC - HOPE - Tucson
- Arizona Oncology Associates, PC - HOPE - Tucson
Alabama
- University of South Alabama Health Children's and Women's Hospital - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
- University of South Alabama Health University Hospital - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2019-10-02 |
| Est. Completion | 2029-03-10 |
| Phase | Phase 3 |
What the registry record for NCT03975647 still lists
NCT03975647 is an interventional study that assigns participants to a tested intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, above the 228-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (104% higher).
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT03975647 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03975647 about?
NCT03975647 is a clinical study titled "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer". This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the bod...
What is the current status of trial NCT03975647?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2019-10-02. Estimated completion is 2029-03-10.
What conditions does trial NCT03975647 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT03975647?
The interventions under investigation include: placebo (DRUG), T-DM1 (DRUG), tucatinib (DRUG).
Who is sponsoring clinical trial NCT03975647?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03975647 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03975647's enrollment target sits among peer trials
466 7th of 58 higher than 52 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
RECRUITING · Phase 3
-
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
- NCT07214779 · 466 participants · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI